{"transactions":[{"id":703962,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2026-07-23T20:15:03.000Z","date":"2026-07-23","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in four equal installments beginning on July 23, 2027, in each case subject to the Reporting Person's continuous employment with the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":500000,"source":{"system":"sec-edgar","filing":"0001982278-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1227636/000198227826000006/ownership.xml","form_type":"4"}},{"id":770345,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T22:02:22.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0.7,"value":126000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":180000,"derivative":{"exercise_price":0.7,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-26-064652","document":"tm267728-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926064652/tm267728-2_4seq1.xml","form_type":"4"}},{"id":1312355,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-01-06T23:39:06.000Z","date":"2025-01-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":39132,"price":15.22,"value":595589.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares  sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold  on January 6, 2025 in multiple transactions at prices ranging from $14.37 to $15.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":260868,"source":{"system":"sec-edgar","filing":"0000805928-25-000002","document":"wk-form4_1736206734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592825000002/wk-form4_1736206734.xml","form_type":"4"}},{"id":1315837,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T22:32:45.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":30666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":31465,"source":{"system":"sec-edgar","filing":"0001104659-25-000890","document":"tm251864-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000890/tm251864-5_4seq1.xml","form_type":"4"}},{"id":1689758,"issuer":{"id":4297,"kind":"organization","name":"Axogen, Inc.","symbol":"AXGN"},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-01-04T22:48:53.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0000805928-24-000009","document":"wk-form4_1704408521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000009/wk-form4_1704408521.xml","form_type":"4"}},{"id":1848088,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":28976,"kind":"person","name":"Naor Nir","position":1,"cik":"0001982278","reported_name":"Naor Nir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T20:06:43.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":11999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on June 19, 2023 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on June 19, 2023 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics Inc. on each vesting date."}],"balance_after":11999,"source":{"system":"sec-edgar","filing":"0001104659-23-073331","document":"tm2319343d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923073331/tm2319343d2_4.xml","form_type":"4"}}]}